Company
Chugai
Chugai has 25 drugs tracked on RxWires: 2 post-market, 11 in Phase 3, 4 in Phase 2, 8 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Eldecalcitol | Post-Market | Osteoporosis in Postmenopausal Women |
| Sevelamer HCl | Post-Market | Hemodialysis |
| R744 | Phase 3 | Hemodialysis Patients |
| cisplatin | Phase 3 | Sarcoma |
| MRA(Tocilizumab) | Phase 3 | Systemic Juvenile Idiopathic Arthritis |
| Paclitaxel + bevacizumab therapy | Phase 3 | Breast Cancer |
| recombinant human erythropoietin | Phase 3 | Chemotherapy Induced Anemia |
| peginterferon alfa-2a 180μg | Phase 3 | Liver Cirrhosis |
| Trastuzumab | Phase 3 | HER2-positive Locally Advanced or Metastatic Breast Cancer |
| ED-71 | Phase 3 | Osteoporosis |
| ibandronic acid 0.5mg | Phase 3 | Primary Osteoporosis |
| peginterferon alfa-2a | Phase 3 | Chronic Hepatitis C |
| Tocilizumab + methotrexate(MTX) | Phase 3 | Rheumatoid Arthritis (RA) |
| RiBVD | Phase 2 | Mantle Cell Lymphoma |
| nemolizumab (CIM331) | Phase 2 | Atopic Dermatitis |
| Bevacizumab | Phase 2 | Metastatic Colorectal Cancer |
| tocilizumab and IV steroids combination | Phase 2 | Giant Cell Arteritis |
| SAIL66 | Phase 1 | Solid Tumor |
| AUBE00 | Phase 1 | Solid Tumors |
| AQUA07 | Phase 1 | ALK Positive Non-small Cell Lung Cancer |
| ROSE12 | Phase 1 | Solid Tumor |
| ERY974 | Phase 1 | Solid Tumors |
| RO5126766 | Phase 1 | Advanced Non-small Cell Lung Cancer |
| Codrituzumab | Phase 1 | Primary Extra-cranial Solid Tumor |
| PCO371 | Phase 1 | Healthy Volunteers |
Latest
No recent events.
Follow Chugai on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.